TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03764618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib disodium
Description: Fostamatinib (100mg PO bid or 150 mg PO bid)~The dose may be reduced at any time to a dose as low as fostamatinib 100 mg PO qd or matching placebo if dose limiting adverse events are observed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04597697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin icodec
Description: Insulin icodec will be investigated in participants with impaired liver function and subjects with normal liver function. Administered as a single dose subcutaneously (under the skin) The study will last for about 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin icodec
Description: Insulin icodec will be investigated in participants with impaired liver function and subjects with normal liver function. Administered as a single dose subcutaneously (under the skin) The study will last for about 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin icodec
Description: Insulin icodec will be investigated in participants with impaired liver function and subjects with normal liver function. Administered as a single dose subcutaneously (under the skin) The study will last for about 8 weeks.
Study: NCT02099188

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy - Patients needing Elective Nodal Volume (ENI)
Description: LR-PTV: 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed. This volume will always be treated with photons IMRT.~1. Particle boost with ENI:~   HR-PTV: carbon ions 18 - 21 Gy (relative biological effectiveness, RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy IR-PTV: this volume is optional, if used it will receive the first 3 fractions i.e. 9 Gy (RBE) of the boost.~2. Photons boost with ENI. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy - Patients not needing ENI
Description: 1. Treatment with particles. IR-PTV: this volume can be larger or equal to HR-PTV according to individual situations. 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed to IR-PTV with protontherapy with concomitant chemotherapy. HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy. The first 3 fractions may be given to the bigger IR-PTV.~2. Treatment with photons. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy - Patients needing curative neck irradiation
Description: LR-PTV: 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed. This volume will always be treated with photons IMRT.~1. Particle boost. HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy IR-PTV: this volume is optional, if used it will receive the first 3 fractions i.e. 9 Gy (RBE) of the boost.~2. Photons boost. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical and postoperative setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed.
Study: NCT02226003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin
Description: Ertugliflozin, 5 mg or 15 mg, administered orally, once daily for 26 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin
Description: Ertugliflozin, 5 mg or 15 mg, administered orally, once daily for 26 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin, 100 mg, administered orally, once daily for 26 weeks.
Study: NCT04298424

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PLSM
Description: The program was designed for implementation over 4 consecutive weeks, with groups of 6-8 people each attending one 60-90-minute class per week. Peer leaders lead the groups to promote interaction, sharing, and support, and assist in goal setting to address behavior-related health problems, and thereby the development and implementation of strategies to achieve suitable, sustainable, and feasible self-management behavior.
Study: NCT00031460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyclovir
Description: Oral banana flavored acyclovir suspension: 300 mg/m\^2/dose three times a day (TID), to be given at least 6 to 8 hours apart for 6 months. Dosage adjustments will be made monthly to compensate for increases in body surface area.
Study: NCT04597697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin icodec
Description: Insulin icodec will be investigated in participants with impaired liver function and subjects with normal liver function. Administered as a single dose subcutaneously (under the skin) The study will last for about 8 weeks.
Study: NCT00031460

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral banana flavored placebo suspension: to be given at least 6 to 8 hours apart for 6 months. Dosage adjustments will be made monthly to compensate for increases in body surface area.
Study: NCT02198794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SD-809
Description: SD-809 will be administered per dose and schedule specified in the arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SD-809
Description: SD-809 will be administered per dose and schedule specified in the arm.
Study: NCT00852202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cariprazine
Description: Drug: cariprazine (0.25 - 0.75 mg/day)
Study: NCT02198794

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SD-809
Description: SD-809 will be administered per dose and schedule specified in the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SD-809
Description: SD-809 will be administered per dose and schedule specified in the arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to SD-809 will be administered per schedule specified in the arm.
Study: NCT01932255

Intervention type: PROCEDURE
Intervention: prophylactic spinal tap

Intervention type: PROCEDURE
Intervention: no prophylactic spinal tap
Study: NCT03107988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Description: Lorlatinib will be given orally once daily continuously in 28-day cycles. Lorlatinib will be provided as 5 mg or 25 mg tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Description: Lorlatinib will be given orally once daily continuously in 28-day cycles. Lorlatinib will be provided as 5 mg or 25 mg tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Description: Lorlatinib will be given orally once daily continuously in 28-day cycles. Lorlatinib will be provided as 5 mg or 25 mg tablets.
Study: NCT02226003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin, 100 mg, administered orally, once daily for 26 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Ertugliflozin
Description: Matching placebo to ertugliflozin administered orally, once daily for 26 weeks.
Study: NCT02813304

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gradual reloading
Description: Participants will be asked to perform isometric strengthening exercises in lateral rotation and abduction. Participants will place their affected arm by the side with the elbow gently tucked in close to the body, elbow flexed at 90°, and the thumb pointing upwards. The opposite hand will resist the lateral rotation and abduction. They will be asked to push against the uninvolved hand, building up to sub-maximal pressure (approximately 50% to 75% of the maximum possible force) over five seconds. Then the contraction will be slowly released. A maximum pain level of 5/10 will be accepted when performing the contraction. Elevation movements will also be performed 3 times a day in the frontal, sagittal and scapular plane.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rest and cryotherapy
Description: Participants will be asked to apply ice wrap on their painful shoulder 3 times a day over the area of pain for 15 minutes. They will be asked to place the ice wrap inside a damp towel cloth (minimise the risk of an ice burn) and secure around the shoulder with a towel. After the 15 minutes, they will be asked to perform gentle, slow, pain free shoulder movements that do not provoke pain. All participants will be provided with a commercial ice wrap. They will also be asked to avoid painful movements, working above shoulder level, repeated or sustained elevation movements and lifting weights.
Study: NCT03107988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Description: Lorlatinib will be given orally once daily continuously in 28-day cycles. Lorlatinib will be provided as 5 mg or 25 mg tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 250mg/m2/day will be administered as a 30 minute IV infusion on days 1-5 of each cycle
Study: NCT03500276

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga program
Description: Yoga classes will be conducted 2xweekly/ 90 minutes and consist of physical exercises (asanas), breathing exercises (pranayama), relaxation and self-enquiry meditation based on Yoga in daily life system.
Study: NCT02226003

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Ertugliflozin
Description: Matching placebo to ertugliflozin administered orally, once daily for 26 weeks.
Study: NCT03107988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Topotecan 0.75mg/m2/day will be administered as a 30 minute IV infusion immediately following cyclophosphamide on days 1-5 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim/pegfilgrastim
Description: Filgrastim is to be given with each course beginning 24-48 hours following completion of cyclophosphamide and topotecan and continued through post-nadir count recovery with an ANC \> 2000/mm\^3 at 5mcg/kg/day. Filgrastim must be discontinued at least 24 hours prior to the start of the next course of therapy.~Pegfilgrastim (100mcg/kg; 6mg maximum dose) may be substituted and is given one time at 24-48 hours from completion of cyclophosphamide and topotecan.
Study: NCT00007267

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Disease/health education

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-help cognitive behavioral intervention facilitated by a psychologist
Study: NCT01586455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Placental Derived Stem Cell
Description: Infusions of thawed HPDSC to be given following UCB infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Placental Derived Stem Cell
Description: Infusions of thawed HPDSC to be given following UCB infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Placental Derived Stem Cell
Description: Infusions of thawed HPDSC to be given following UCB infusion.
Study: NCT02226003

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Sitagliptin
Description: Matching placebo to sitagliptin administered orally, once daily for 26 weeks.
Study: NCT00852202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cariprazine
Description: Drug: cariprazine (1.5 - 3.0 mg/day)
Study: NCT02226003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride
Description: Open-label glimepiride rescue therapy will be initiated at 1 or 2 mg/day and may be titrated to the maximum labeled dose or maximum tolerated dose (if lower than labeled dose), as considered appropriate by the investigator, based on blood glucose measurements and in accordance with the local, approved label.
Study: NCT01586455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Placental Derived Stem Cell
Description: Infusions of thawed HPDSC to be given following UCB infusion.
Study: NCT03891914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography using 18F-FCH
Description: Positron Emission Tomography imaging coupled with scanner (PET-CT). with the injection of a radiopharmaceutical drug, the 18F-FCH(or fluorocholine) for the detection of bone lesions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography using 18F-FDG
Description: Positron Emission Tomography imaging coupled with scanner (PET-CT). with the injection of a radiopharmaceutical drug, the 18F-FDG (or fluorodeoxyglucose) for the detection of bone lesions
Study: NCT02226003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride
Description: Open-label glimepiride rescue therapy will be initiated at 1 or 2 mg/day and may be titrated to the maximum labeled dose or maximum tolerated dose (if lower than labeled dose), as considered appropriate by the investigator, based on blood glucose measurements and in accordance with the local, approved label.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glimepiride
Description: Open-label glimepiride rescue therapy will be initiated at 1 or 2 mg/day and may be titrated to the maximum labeled dose or maximum tolerated dose (if lower than labeled dose), as considered appropriate by the investigator, based on blood glucose measurements and in accordance with the local, approved label.
Study: NCT01400516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: 20 μg, subcutaneous injection, 1 injection per day

Intervention type: DRUG
Group type: OTHER
Intervention: calcium citrate
Description: 1000 mg of calcium citrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcium citrate
Description: 1000 mg of calcium citrate

Intervention type: DRUG
Group type: OTHER
Intervention: Vitamin D
Description: 800 IU of Vitamin D

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 800 IU of Vitamin D
Study: NCT03500276

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Arthritis-education
Description: Arthritis-education classes will be conducted 1xweekly/ 120 minutes and led by rheumatology specialists and consist of lectures on arthritis and related issues followed by group discussion.
Study: NCT04707599

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reminder plus (telephone call from therapist)
Description: Reminder plus (telephone call from therapist)
Study: NCT00852202

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsules, oral administration, once daily dosing
Study: NCT06021418

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DKB-119
Description: Experimental and Acitve Comparator are applied 4 times to each of crow's feet on both sides of the subject.
Study: NCT01049854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Full Intensity with TBI
Description: Patients will start their pre-conditioning regimen on Day -8. Fractionated TBI will be administered twice daily for 3 days on Days -8, -7, and -6. Patients will receive Thiotepa on Days -5, -4, Cyclophosphamide on Days -3, -2 and rabbit antithymocyte globulin on Days -4, -3, -2 and -1. The stem cell infusion will be performed on Day 0. GM-CSF hematopoietic growth factor will start on Day 0. GVHD prophylaxis will consist of tacrolimus only.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Full Intensity
Description: Patients will start their pre-conditioning regimen on Day -9. Patients will receive busulfan twice daily on Days - 8, -7, -6, and -5 and Melphalan on Days -4, -3 and -2 and rabbit antithymocyte globulin on Days -4, -3, -2 and -1 with stem cell infusion on Day 0. GM-CSF hematopoietic growth factor will start on Day 0. GVHD prophylaxis will consist of tacrolimus only.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reduced Intensity
Description: Patients will start their GVHD prophylaxis with Tacrolimus on Day -9. Patients will receive busulfan twice daily on Days -8, -7, -6, and -5; fludarabine on Days -7, -6, -5, -4, -3 and -2 and alemtuzumab on Days -5, -4, -3, -2, and -1. The stem cell infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus only.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reduced Intensity (Fanconi)
Description: Patients will start their pre-conditioning regimen on Day -6. Patients will receive TBI as a single fraction on Day -6. Patients will receive fludarabine and cyclophosphamide on Days - 5, -4, -3, and -2 and antithymocyte globulin (horse) on Days -5, -4, -3, -2 and -1. The stem cell infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus only.
Study: NCT04070937

Intervention type: DIAGNOSTIC_TEST
Intervention: vestibular test 1
Description: videonystagmography

Intervention type: DIAGNOSTIC_TEST
Intervention: vestibular test 1
Description: videonystagmography

Intervention type: DIAGNOSTIC_TEST
Intervention: vestibular test 2
Description: video head impulse test

Intervention type: DIAGNOSTIC_TEST
Intervention: vestibular test 2
Description: video head impulse test

Intervention type: DIAGNOSTIC_TEST
Intervention: vestibular evoked myogenic potentials
Description: vestibular evoked myogenic potentials to measure the function of otolith organs
Study: NCT06021418

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DKB-119
Description: Experimental and Acitve Comparator are applied 4 times to each of crow's feet on both sides of the subject.
Study: NCT00022113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cilengitide
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00786409

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Gardasil
Description: 0.5 ml Gardasil vaccine will be administered to each patient at months 0,2 and 6.
Study: NCT03893630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic Acid 81 mg
Description: Patients will receive 81mg acetylsalicylic acid daily, initiated between 11 and 16 weeks of gestation and continued until 36 weeks of gestation.
Study: NCT00212615

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin (Eloxatin)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin (Eloxatin)
Study: NCT03893630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic Acid 162 mg
Description: Patients will receive 162mg acetylsalicylic acid daily, initiated between 11 and 16 weeks of gestation and continued until 36 weeks of gestation.
Study: NCT01400516

Intervention type: DRUG
Group type: OTHER
Intervention: TNF antagonist
Description: TNF antagonist as prescribed in clinical practice (such as etanercept or adalimumab)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNF antagonist
Description: TNF antagonist as prescribed in clinical practice (such as etanercept or adalimumab)
Study: NCT00564655

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine with epinephrine (mid and upper abdomen)
Description: Patients will receive localized infiltration of local anesthesia (0.25% bupivacaine with epinephrine 1:200,000) at the beginning of the procedure as is current standard practice. Localized anaesthetic of the mid and upper abdomen.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bupivacaine with epinephrine (transversus abdominis plane)
Description: 0.6 cc/kg (to a maximum of 20 ccs) of 0.25% bupivacaine with epinephrine 1:200,000 will be injected into the neuro-vascular plane between the internal oblique and transversus abdominis muscles. Regional anaesthetic block of the transversus abdominis plane.
Study: NCT03226340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-amlodipine 2.5mg + Chlorthalidone 25mg
Description: patients will receive S-amlodipine 2.5mg + Chlorthalidone 25mg p.o. once a day for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-amlodipine 2.5mg + Telmisartan 40mg
Description: patients will receive S-amlodipine 2.5mg + Telmisartan 40mg p.o. once a day for 12 weeks.
Study: NCT02023450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saquinavir and ritonavir
Description: micro and low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saquinavir and ritonavir
Description: standard dose
Study: NCT04400903

Intervention type: DEVICE
Intervention: Activity Monitor
Description: Undergo HRV monitoring via WHOOP device

Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study: NCT01116258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5847
Description: oral suspension, 15 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral suspension, 15 days
Study: NCT01220258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin ophthalmic solution, 1%
Description: 1 drop twice daily (BID) for the first 2 days and then 1 drop once daily (QD) for the remainder of treatment period (approximately 28 days total)
Study: NCT02159755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT03404622

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IUCD
Description: IUCD will be inserted in 100 women post placental removal and will be inserted in anther 100 women after six weeks post cesarean delivery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IUCD
Description: IUCD will be inserted in 100 women post placental removal and will be inserted in anther 100 women after six weeks post cesarean delivery